FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES
Purpose: Colorectal cancer is the second leading cause of cancer mortality in the USA. According to Bulgarian National Statistics Institute, 2370 colon and 1664 rectal cancer cases were diagnosed in 2012 with total number of patients 29995. Adding bevacizumab to chemotherapy in patients with metasta...
Main Authors: | Assia Konsoulova, Ivan Donev, Nikolay Conev, Sonya Draganova, Nadezhda Petrova, Eleonora Dimitrova, Hristo Popov, Kameliya Bratoeva, Petar Ghenev |
---|---|
Format: | Article |
Language: | English |
Published: |
Peytchinski Publishing
2016-03-01
|
Series: | Journal of IMAB |
Subjects: | |
Online Access: | http://www.journal-imab-bg.org/issues-2016/issue1/JofIMAB_2016-22-1p1039-1044.pdf |
Similar Items
-
Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
by: Eudocia Q. Lee, et al.
Published: (2019-10-01) -
Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series
by: Ryota Tamura, et al.
Published: (2020-03-01) -
A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
by: Ryota Tamura, et al.
Published: (2020-09-01) -
Intravitreal bevacizumab versus bevacizumab and 1 mg triamcinolone acetonide in eyes with bilateral diabetic macular edema
by: Sever Ozkan, et al.
Published: (2019-01-01) -
Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy
by: Faheem Shaik, et al.
Published: (2020-12-01)